Franklin Resources Inc. Purchases 6,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Franklin Resources Inc. lifted its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 0.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,308,546 shares of the company’s stock after buying an additional 6,000 shares during the period. Franklin Resources Inc. owned about 1.75% of Centessa Pharmaceuticals worth $38,668,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after buying an additional 865 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock valued at $317,000 after acquiring an additional 5,316 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of Centessa Pharmaceuticals in the third quarter worth approximately $187,000. Wellington Management Group LLP raised its holdings in shares of Centessa Pharmaceuticals by 14.4% during the fourth quarter. Wellington Management Group LLP now owns 115,107 shares of the company’s stock valued at $1,928,000 after purchasing an additional 14,494 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Centessa Pharmaceuticals by 68.7% during the third quarter. Geode Capital Management LLC now owns 56,597 shares of the company’s stock valued at $905,000 after purchasing an additional 23,058 shares during the period. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on CNTA shares. Morgan Stanley reaffirmed an “overweight” rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. TD Cowen initiated coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Piper Sandler started coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an “overweight” rating and a $38.00 target price on the stock. Finally, Guggenheim restated a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $27.71.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $11.68 on Friday. The stock has a 50-day simple moving average of $16.18 and a two-hundred day simple moving average of $16.33. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals plc has a 52-week low of $7.75 and a 52-week high of $19.09. The firm has a market capitalization of $1.56 billion, a PE ratio of -7.63 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.04. Analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Insider Transactions at Centessa Pharmaceuticals

In other news, CTO Tia L. Bush sold 11,000 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $16.86, for a total value of $185,460.00. Following the completion of the transaction, the chief technology officer now owns 121,503 shares of the company’s stock, valued at $2,048,540.58. This represents a 8.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $15.29, for a total value of $91,740.00. Following the sale, the general counsel now directly owns 118,265 shares in the company, valued at $1,808,271.85. This trade represents a 4.83 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 260,168 shares of company stock valued at $4,309,568 over the last three months. Corporate insiders own 11.59% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.